FDA charge sees Genzyme's Q1 results plummet
This article was originally published in Scrip
Executive Summary
Genzyme will be forced to pay out $175 million of its profits following a draft consent decree from the US FDA over its troubled manufacturing plant in Allston, Massachusetts.